HDAC-driven mechanisms in anticancer resistance:epigenetics and beyond  

作　　者：Martina Minisini Martina Mascaro Claudio Brancolini 

机构地区：[1]Laboratory of Epigenomics,Department of Medicine,Universitàdegli Studi di Udine,Udine 33100,Italy

出　　处：《Cancer Drug Resistance》2024年第1期166-188,共23页癌症耐药(英文)

基　　金：Research work in the CB lab is supported by AIRC under IG 2021-ID.26200 project;Interreg Italia Osterreich ITAT11-018 SENECA,CIB“Modelli innovativi per applicazioni di scienze omiche avanzate-Tecnologie innovative per le scienze omiche avanzate in modelli umani e vegetali”.

摘　　要：The emergence of drug resistance leading to cancer recurrence is one of the challenges in the treatment of cancer patients.Several mechanisms can lead to drug resistance,including epigenetic changes.Histone deacetylases(HDACs)play a key role in chromatin regulation through epigenetic mechanisms and are also involved in drug resistance.The control of histone acetylation and the accessibility of regulatory DNA sequences such as promoters,enhancers,and super-enhancers are known mechanisms by which HDACs influence gene expression.Other targets of HDACs that are not histones can also contribute to resistance.This review describes the contribution of HDACs to the mechanisms that,in some cases,may determine resistance to chemotherapy or other cancer treatments.

关 键 词：HDACS chemotherapy hormone deprivation ACETYLATION palbociclib PARP DNA damage 

分 类 号：R73[医药卫生—肿瘤]